November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Facial resurfacing with erbium:YAG laser
September 1st 2005New Orleans - Results of a study comparing the carbon dioxide (CO2) laser and the dual-mode long-pulsed erbium:YAG laser for ablative facial resurfacing demonstrated that patients in the erbium:YAG laser group experienced less scarring and fewer pigmentary changes, according to John L. Burns, M.D., of Dallas Plastic Surgery Institute, Dallas.
Autologous cellular treatments show long-term results with contour defects
September 1st 2005Baltimore - Results of an exploratory phase 3 clinical trial demonstrate that injection of autologous living skin fibroblasts provides safe and effective correction of facial contour deformities that is sustained for at least 12 months, reports Robert A. Weiss, M.D.
Rejuvenating the face: New trends emerge
September 1st 2005National report - Even as new techniques, devices and pharmaceutical developments for facial contouring and wrinkle refinement proliferate for dermatologists and cosmetic surgeons, two trends are gaining momentum - one for the better and one for the worse, according to dermatologist David H. McDaniel, M.D., and his colleague, cosmetic surgeon Kyle S. Choe, M.D.
Hair removal technologies expanding
September 1st 2005Chicago — As the array of laser and light sources for hair removal continues to grow, so does their efficacy and safety, according to Vic Narurkar, M.D., a dermatologist in private practice and assistant clinical professor of dermatology at the University of California, Davis, School of Medicine (and president-elect of the American Society of Cosmetic Dermatology and Aesthetic Surgery).
MAL-PDT clears Bowen's disease with excellent cosmesis
September 1st 2005National report — Photodynamic therapy using the topical photosensitizer methyl aminolevulinate 16 percent cream (Metvix, Galderma) is a non-invasive, well-tolerated, effective treatment for Bowen's disease, offering excellent cosmetic results, according to the findings of a multicenter, randomized, active- and placebo-controlled study, says Colin A. Morton, M.D., consultant dermatologist, Falkirk Royal Infirmary, Falkirk, Scotland.
New fillers finding favor in facial esthetic enhancement
September 1st 2005National report — The use of facial fillers to help counteract the effects of facial aging is becoming more widespread, with new techniques and products springing up regularly. In a recent seminar, Paul M. Friedman, M.D., comprehensively covered the topic of facial fillers, with a focus on the hyaluronic acid products.
Restraint helps avoid filler pitfalls
September 1st 2005Chicago — As physicians increasingly use injectable fillers and botulinum toxin as complementary treatments for facial rejuvenation, success depends on educating patients thoroughly and injecting products cautiously, says Seth L. Matarasso, M.D., clinical professor of dermatology at the University of California, San Francisco, School of Medicine.
Periocular sclerotherapy requires modifications
September 1st 2005Chicago — Traditionally used to treat unwanted veins in the legs and thighs, sclerotherapy can provide an effective tool in other areas as well, according to David Green, M.D., a Bethesda, Md.-based private practitioner and clinical assistant professor of dermatology at Howard University Hospital, Washington, D.C.
Incisionless technique corrects wrinkles, lines, scars
September 1st 2005New Orleans - A new procedure releases skin attachments of deep wrinkles, scars and folds notoriously difficult to correct with traditional techniques, says to Miles H. Graivier, M.D. The subcision or release of skin attachments is performed with a braided wire attached to two long, straight needles (Nutec International) and takes little time for a plastic surgeon to learn, Dr. Graivier adds. He presented this technique at the Aesthetic Meeting 2005 sponsored by the American Society of Aesthetic Plastic Surgery (ASAPS), here.
Equipotent doses of botulinum toxin type A products share same radius of action
September 1st 2005The two commercially available formulations of botulinum toxin type A - Botox Cosmetic (Allergan) and Dysport (Ipsen/Inamed) - produce similar "action halos" when injected into the frontalis muscle under identical conditions to treat horizontal frown lines, says Doris M. Hexsel, M.D., private practitioner in Porto Alegre, Brazil, and former professor of dermatology, University of Passo Fundo School of Medicine, Brazil.
TriLuma combination effective for PIH
September 1st 2005Kissimmee, Fla. — With recent developments in the treatment of hyperpigmentation, Dr. Roger Ceilley, clinical professor of dermatology at the University of Iowa and past president of the American Academy of Dermatology and the American Society for Dermatologic Surgery, provided further insight into the management of post-inflammatory hyperpigmentation.